CD69 and neoplasm: Our data demonstrate that T cells from CAR-M-cured mice mounted robust tumor-specific responses upon re-exposure to tumor cells, characterized by rapid activation (CD69), proliferation, and effector cytokine (IL-2, IFN-γ) production (Fig. 7D-F).